These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 36476337)
1. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives. Boch T; Köhler J; Janning M; Loges S Cancer Biol Med; 2022 Dec; 19(11):1543-64. PubMed ID: 36476337 [TBL] [Abstract][Full Text] [Related]
2. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies. Bai Q; Wang J; Zhou X Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723 [TBL] [Abstract][Full Text] [Related]
3. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
4. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. Brazel D; Kroening G; Nagasaka M BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589 [TBL] [Abstract][Full Text] [Related]
6. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. Hamada A; Suda K; Nishino M; Obata K; Oiki H; Fukami T; Fukuda S; Fujino T; Ohara S; Koga T; Chiba M; Shimoji M; Ito M; Takemoto T; Soh J; Tsutani Y; Mitsudomi T J Thorac Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 37666482 [TBL] [Abstract][Full Text] [Related]
7. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Nagasaka M; Balmanoukian AS; Madison R; Zhang SS; Klempner SJ; Ou SI Lung Cancer; 2022 Feb; 164():52-55. PubMed ID: 35032819 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275 [TBL] [Abstract][Full Text] [Related]
9. The development of amivantamab for the treatment of non-small cell lung cancer. Brazel D; Nagasaka M Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647 [TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844 [TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179 [TBL] [Abstract][Full Text] [Related]
12. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations. Hernandez L; Young M J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869 [No Abstract] [Full Text] [Related]
13. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer. Seo D; Lim JH Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892105 [TBL] [Abstract][Full Text] [Related]
14. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Socinski MA; Villaruz LC; Ross J Oncologist; 2017 Jan; 22(1):3-11. PubMed ID: 27821794 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
16. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. Zhang H Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501 [TBL] [Abstract][Full Text] [Related]
19. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Gazdar AF Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293 [TBL] [Abstract][Full Text] [Related]
20. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Zhao Y; Wang H; He C J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]